About Amplitude
Amplitude is a venture capital firm founded in 2018. It is primarily based out of Montreal, Canada. As of Mar 2026, Amplitude is an active investor, having invested in 30 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in Canada based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series B round of Congruence Therapeutics Overall, Amplitude portfolio has seen 4 IPOs and 4 acquisitions including key companies like Zymeworks, Evommune and Profound Medical. A lot of funds co-invest with Amplitude, with names like Fonds de solidarite FTQ sharing a substantial percentage of its portfolio. Amplitude has team of 16 people including 6 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Amplitude's List of Top Investments
Amplitude has a portfolio of 30 companies. Their most notable investments are in Reverb Therapeutics and Fluid Biomed.Their portfolio spans across Canada, United States, Israel and 1 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 1 other sectors, across stages such as Series B, Seed and 1 more. Here is the list of top investments by Amplitude:1. Zymeworks
Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. The company’s Azymetric and AlbuCORE platforms, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
Key facts about Zymeworks
- Founded Year: 2003
- Location: Vancouver (Canada)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $146M
- Employee Count: 264 as on Aug 31, 2026
- Investors: Perceptive Advisors, Teralys Capital and 17 Others
- Latest Funding Round: Post IPO, Dec 26, 2023, $*****
- Highlight: Public
2. Evommune
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Key facts about Evommune
- Founded Year: 2020
- Location: Sacramento (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $276M
- Employee Count: 69 as on Aug 31, 2026
- Investors: RTW Investments, Marshall Wace and 18 Others
- Latest Funding Round: Post IPO, Feb 12, 2026, $*****
- Highlight: Public
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
Key facts about Profound Medical
- Founded Year: 2008
- Location: Toronto (Canada)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $37.7M
- Employee Count: 182 as on Aug 31, 2026
- Investors: Stifel, FedDev Ontario and 11 Others
- Latest Funding Round: Post IPO, Dec 19, 2025, $*****
- Highlight: Public
AI-powered platform for RNA biology to accelerate genetic therapy discovery. It focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions. Its offers proprietary AI platform including the flagship model BigRNA that uses machine learning to analyze vast RNA biology data, identify therapeutic targets, and evaluate potential therapeutic candidates efficiently than traditional approaches. The technology helps accelerate early stages of drug discovery and design of RNA-based therapies.
Key facts about Deep Genomics
- Founded Year: 2014
- Location: Toronto (Canada)
- Stage: Series C
- Total Funding till date: $238M
- Employee Count: 111 as on Aug 31, 2026
- Investors: Fidelity Investments, Deep Learning and 16 Others
- Latest Funding Round: Series C, Jul 28, 2021, $*****
- Highlight: Editors' Pick
5. Fluid Biomed
Developer of medical device to treat brain aneurysms. The company has developed a hybrid polymer-metal flow-diverting stent to cure brain aneurysms. Also, its proprietary stent delivery system is used to navigate to bypass the aneurysm under angiographic guidance.
Key facts about Fluid Biomed
- Founded Year: 2012
- Location: Calgary (Canada)
- Stage: Series A
- Total Funding till date: $32.5M
- Employee Count: 49 as on May 27, 2025
- Investors: Amplitude, IAG Capital Partners and 13 Others
- Latest Funding Round: Series A, Dec 16, 2024, $*****
- Highlight: Editors' Pick
Amplitude's Year-on-Year Investment Trends
Amplitude has invested in 30 companies over the last 6 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 3 investments, while as of Mar 2026, it has made 1 investment in this year. Its most recent first time investment was in Mediar Therapeutics and most recent follow-on round was in Congruence Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 1 | 2 | 3 |
2024 | 2 | 3 | 5 |
2023 | 5 | 2 | 7 |
2022 | 4 | 0 | 4 |
2021 | 6 | 1 | 7 |
2020 | 1 | 0 | 1 |
Amplitude's Investments by Stage
Amplitude has made 7 investments in Series B stage with an average round size of $53.8M, 6 investments in Seed stage with an average round size of $9.7M and 6 investments in Series A stage with an average round size of $42.3M.Stage of entry | No. of Investments |
|---|---|
Series B | 7 |
Seed | 6 |
Series A | 6 |
Note: We have considered here, only first round of investments
Amplitude's Investments by Sector
Amplitude has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Artificial Intelligence - Industry Applications and High Tech. Notably, it has invested in 30 Tech companies, 29 Enterprise (B2B) companies, 8 Software companies and at least 4 companies focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 19 |
HealthTech | 6 |
Enterprise Applications | 5 |
Artificial Intelligence - Industry Applications | 4 |
High Tech | 2 |
Others | 3 |
Note: We have considered here, only first round of investments
Amplitude's Investments by Geography
Amplitude has made most investments in Canada (14), followed by United States where it has made 4 investments.Country | No. of Investments |
|---|---|
Canada | 14 |
United States | 4 |
Israel | 1 |
Note: We have considered here, only first round of investments
Amplitude's recent investments
Amplitude has made 1 investments in 2026 so far - Congruence Therapeutics.Here are the most recent investments by Amplitude:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 23, 2026 | Canada | Series B | 5290 | [+7] | |
Dec 10, 2025 | United States | Series B | 5071 | ||
Sep 04, 2025 | Canada | Series B | 9760 | [+7] | |
Feb 19, 2025 | Canada | Seed | 8350 | ||
Dec 16, 2024 | Canada | Series A | 8035 | [+3] |
IPOs and Publicly Listed companies in Amplitude's Portfolio
4 of Amplitude's portfolio companies have become public. Evommune got listed on the New York Stock Exchange (NYSE), in Nov 2025 at marketcap of $481M and Milestone Pharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $355M.Here are Amplitude's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 06, 2025 | Mar 28, 2023 | Series B | 6148 | |
May 09, 2019 | - | - | 3511 | |
May 17, 2017 | - | - | 1902 | |
Apr 28, 2017 | - | - | 6863 |
Acquired companies in Amplitude's Portfolio
4 companies from Amplitude's portfolio have been acquired. The most recent acquisition was Repare Therapeutics in Nov 2025 by XenoTherapeutics for $*****.Here are Amplitude's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 14, 2025 | - | - | 1818 | |
Jun 27, 2024 | Mar 24, 2022 | Series B | 6409 | |
May 08, 2023 | Dec 15, 2021 | Seed | 1893 | |
Feb 25, 2019 | - | - | 2480 |
Team profile of Amplitude
Amplitude has a team of 16 members including 6 Partners, 1 Venture Partner and 3 Principals located in Canada. Amplitude's team sits on the board of 2 companies.Here is a list of top team members in Amplitude:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Montreal | |||
Partner | Montreal | - | ||
Partner | Montreal | - | ||
Partner | Toronto | - | ||
Partner | Ottawa | - | ||
Partner | Vancouver | - | ||
Partner | Vancouver | - | - | |
Venture Partner | - | - | ||
Principal | Toronto | - | ||
Principal | Calgary | - | ||
Principal | Montreal | - |
Co-investors of Amplitude
Over the past 6 years, 143 investors have co-invested in Amplitude's portfolio companies. This includes funds and angels.
- Invested before Amplitude: Bluesky Equities, Threshold Impact and 49 others have invested in rounds before Amplitude. There are 2 companies where Bluesky Equities has invested before Amplitude and 2 companies where Threshold Impact has invested before Amplitude.
- Top Co-investors of Amplitude: 57 investors entered a company along with Amplitude. These include investors like Fonds de solidarite FTQ (4 companies).
- Invested after Amplitude: A total of 35 investors have invested in Amplitude's portfolio after their investments. Top Investors include RTW Investments (2 companies), Alexandria (2 companies) and Invest Quebec (2 companies).
Recent News related to Amplitude
•
Congruence Therapeutics Raises $39.5M in FundingFinSMEs•Mar 23, 2026•Congruence Therapeutics, Dimensions, Amplitude, Invest Quebec and 5 others
•
Mediar gains $76M for clinical trials of three fibrosis drugsEndpoints•Jan 06, 2026•Mediar Therapeutics, ICG, Amplitude, Alexandria and 2 others
•
Congruence Therapeutics Raises $32M in FundingFinSMEs•Sep 04, 2025•Congruence Therapeutics, Amplitude, Lumira Ventures, Invest Quebec and 4 others
•
Reverb Therapeutics Raises USD $12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify•R™ Platformintelligence360•Feb 27, 2025•Reverb Therapeutics, Amplitude, Myeloma Investment Fund, KdT Ventures and 3 others
•
Reverb Therapeutics Raises USD 12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify•R™ PlatformBusiness Wire•Feb 19, 2025•Reverb Therapeutics, Amplitude, Myeloma Investment Fund, KdT Ventures and 3 others
•
•
•
Evommune raises $115M to accelerate immune drug testsBioPharmaDive•Oct 31, 2024•Evommune, RA Capital Management, Sectoral, B Capital and 14 others
•
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein ProfilingFinancial Post•Sep 17, 2024•Nomic, Amplitude, AVANT BIO, Lux Capital and 2 others
•
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ PlatformBakersfield•Sep 11, 2024•Radiant Biotherapeutics, Gates, Amplitude, BDC and 7 others
